Pfizer withdraws sickle cell drug Oxbryta over safety concerns [Seeking Alpha]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Seeking Alpha
“Pfizer's decision is based on the totality of clinical data that now indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events which require further assessment,” Pfizer ( PFE ) said in a statement released late Wednesday The pharmaceutical giant said Oxbryta will be withdrawn from all markets where it is currently approved. Pfizer ( PFE ) is also discontinuing all clinical trials and expanded access programs involving the product. Pfizer ( PFE ) said it has notified regulators of its findings and the withdrawal. The company added that it does not anticipate the withdrawal to impact its full-year 2024 financial guidance. Shares of Pfizer ( PFE ) were trading largely flat at around 5:50 p.m. ET following the news. Oxbryta was approved by the FDA in 2019. The product is also approved for use in over 35 countries, including members of the European U
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Vertex Pharmaceuticals presents vanzacaftor/tezacaftor/deutivacaftor data [Yahoo! Finance]Yahoo! Finance
- Wall Street Analysts See Vertex (VRTX) as a Buy: Should You Invest? [Yahoo! Finance]Yahoo! Finance
- Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference [Yahoo! Finance]Yahoo! Finance
- Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis ConferenceBusiness Wire
- Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 8/1/24 - Miss
VRTX
Sec Filings
- 9/4/24 - Form 4
- 9/4/24 - Form 4
- 8/30/24 - Form 144
- VRTX's page on the SEC website